Eli Lilly to apply for approval of anti-obesity drug retatrutide in 2027
The Eli Lilly logo appears at the company's office in San Diego, California, on November 21, 2025. Mike Blake |…
Spdr S&P Biotech Etf
The biotechnology recovery is not a farce. These 3 stocks could lead the next bullish leg
The stock market's attention has been focused almost exclusively on artificial intelligence, semiconductors and a handful of large-cap technology companies.…
AstraZeneca trial failure raises bigger questions about its portfolio
AstraZenecaWainua's failed final trial was never expected to have a major financial impact on the company. Most analysts estimate that…
Jim Cramer Says This Former Covid Market Favorite May Finally Be Invested Again
modern Expanding the portfolio beyond infectious diseases is giving investors a new reason to own stocks after years of uncertainty…
Abivax shares soar after new data on drugs for intestinal diseases
Shares of a French biotechnology company Abivax surged on Tuesday after it released new data on its lead drug for…
Biotech IPO window is open, but big pharma M&As set the pace: bankers
Public markets are beginning to reopen for biotech companies after several years of subdued activity. But stronger companies are still…
Lilly, Novo and Pfizer seek new weight loss drugs
Drug makers have only been introducing GLP-1 pills for a few months and are undergoing big changes to the way…
Novartis, Amgen and Eli Lilly's Lp(a) Drugs Aim to Prevent Heart Attacks
Pharma believes it has found the next frontier in heart attack prevention. Novartis, amgen and Eli Lilly are among drugmakers…
Eli Lilly to acquire cancer drug maker Kelonia in deal worth up to $7 billion
Eli Lilly will acquire biotech company Kelonia Therapeutics in a deal worth up to $7 billion, the company said Monday.…
The European pharmaceutical industry is in danger from Trump's policies and China's biotech boom
Boxes of medicines are seen on the shelves of Keencare pharmacy, a member of the Green Light Group, on September…